Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
Supporting allergen-specific immunotherapy by inhibition of Janus kinases.
Allergy 74, 1814-1816 (2019)
Allergen-specific immunotherapy (AIT) is the only disease-modifying and curative treatment for allergic diseases. While in selected indications such as Hymenoptera venom allergy the curative success of AIT is impressingly high, in other disease manifestations it only reduces the symptoms to a certain extend in a fraction of patients. Key problems leading to a reduced efficacy of AIT seem to partly depend on local inflammatory processes that are not only causing side-effects, but additionally feed-back on the specific immune response. Thus, these inflammatory processes also influence the immunologic memory and impair the induction of immune tolerance (1). During the initial phase of AIT, a further increase of Th2 inflammation, including higher levels of allergen-specific IgE has been observed frequently and can be a reason for side-effects and even anaphylactic reactions during AIT.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Other: Opinion
ISSN (print) / ISBN
0105-4538
e-ISSN
1398-9995
Journal
Allergy
Quellenangaben
Volume: 74,
Issue: 9,
Pages: 1814-1816
Publisher
Wiley
Publishing Place
111 River St, Hoboken 07030-5774, Nj Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute for Allergy Research (IAF)